Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
NCT ID: NCT03303170
Last Updated: 2019-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
168 participants
INTERVENTIONAL
2017-09-25
2018-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
NCT02217228
Multiple Arm Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
NCT02219074
Sebacia Postmarket Study of Real-World Use
NCT03818555
A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris
NCT02758041
A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne
NCT03709654
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sebacia Microparticles
Sebacia Microparticles
Topical microparticle suspension
Nd:Yag Laser
Nd:Yag Laser
Laser delivering 1064 nm wavelength light
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sebacia Microparticles
Topical microparticle suspension
Nd:Yag Laser
Laser delivering 1064 nm wavelength light
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 15 inflammatory acne lesions
* Skin phototype I - III
* Able to understand and comply with study requirements
Exclusion Criteria
* Nodulocystic acne
* Ongoing use of medications and/or treatments for acne
* New hormone regimen (used for less than 12 weeks)
* Significant medical or mental health condition
12 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sebacia, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clear Dermatology & Aesthetics Center
Scottsdale, Arizona, United States
Scripps Health
San Diego, California, United States
Miami Dermatology & Laser Institute
Miami, Florida, United States
Meridian Clinical Research
Savannah, Georgia, United States
MediSearch Clinical Trials
Saint Joseph, Missouri, United States
Dermatology, Laser & Vein Institute
Charlotte, North Carolina, United States
Wake Research Associates
Raleigh, North Carolina, United States
International Clinical Research
Murfreesboro, Tennessee, United States
Austin Institute for Clinical Research
Austin, Texas, United States
The Center for Skin Research
Katy, Texas, United States
Premier Clinical Research
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Sponsor Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SEB-0493
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.